Pharma

The NeuraMetrix solution provides Biopharmaceutical companies with a much more precise, accurate, and cost-effective Digital Cognitive Biomarker for Clinical Drug Development
pharmaceutical sales rep meeting with a pharma companypharmaceutical sales rep meeting with a pharma company

The gap

The main issues for drug trials within neurological diseases and psychiatric disorders today are
  • Difficult to successfully develop new drugs when the cohort is based on patients where the disease has already progressed beyond where the drugs can have an impact
  • No ability to monitor "in real-time" the effect on each trial participant
  • Difficult to measure cognitive side effects of their drugs
  • Do not have an early warning system if the drug is not functioning

NeuraMetrix' highly precise and easy to implement digital biomarker fills an important gap long sought after by the biotech and pharmaceutical industry

With the NeuraMetrix digital biomarker drug trials for neurological diseases and psychiatric disorders can:
  • Remove any patients from the cohort where the disease has already progressed beyond where the drugs can have an impact 
  • Ability to monitor "in real-time" what the effect is for each trial participant
  • Measure cognitive side effects of their drugs
  • Get an early warning if the drug is not functioning
This enables biotech and pharmaceutical companies to: 
  • Adopt rapid screening of large cohorts
  • Take immediate corrective action, if necessary
  • Make it easier for the cohort
Resulting in:
  • Better management of drug trials
  • Fewer participants dropping out of drug trials 
  • Less risk
  • Less cost